Targeting Oncogenic Drivers and Signaling Pathways in Lymphoid Malignancies: From Concept to Practice Redaktion: O'Connor, Owen A.; Seymour, John F.; Ansell, Stephen M.
Targeting Oncogenic Drivers and Signaling Pathways in Lymphoid Malignancies: From Concept to Practice Redaktion: O'Connor, Owen A.; Seymour, John F.; Ansell, Stephen M.
Sie sind bereits eingeloggt. Klicken Sie auf 2. tolino select Abo, um fortzufahren.
Bitte loggen Sie sich zunächst in Ihr Kundenkonto ein oder registrieren Sie sich bei bücher.de, um das eBook-Abo tolino select nutzen zu können.
Targeting Oncogenic Drivers and Signaling Pathways in Lymphoid Malignancies A thorough compilation of the many scientific breakthroughs in the ongoing development of precision cancer therapies related to lymphoma Targeting Oncogenic Drivers and Signaling Pathways in Lymphoid Malignancies: From Concept to Practice focuses on lymphoma, an area which has seen a remarkable number of breakthroughs in the ongoing development of precision cancer therapies. Each section on a specific biology or class of drugs has an introductory chapter written by an authority in the field, exclusively focused on the…mehr
Targeting Oncogenic Drivers and Signaling Pathways in Lymphoid Malignancies A thorough compilation of the many scientific breakthroughs in the ongoing development of precision cancer therapies related to lymphoma Targeting Oncogenic Drivers and Signaling Pathways in Lymphoid Malignancies: From Concept to Practice focuses on lymphoma, an area which has seen a remarkable number of breakthroughs in the ongoing development of precision cancer therapies. Each section on a specific biology or class of drugs has an introductory chapter written by an authority in the field, exclusively focused on the science and its relevance to cancer biology. This approach addresses the need for scientists, physicians, and the private sector to understand the broader context of the extraordinary advances that have produced such astonishing advances in the disease. The work primarily focuses on how to understand and translate fundamental principles of basic science into information that can be directly applied to patients - hence the subtitle, From Concept to Practice. To aid in readers' comprehension, the first page of each chapter contains a box entitled 'Take Home Points'. This short text will highlight the major unique points about the information contained within the chapter. Some of the key topics addressed in the work are as follows: * Biological basis of the lymphoid malignancies: fundamental principles of lymphomagenesis and molecular classification of lymphoid malignancies * Targeting programmed cell death: principles for understanding the many types of cell death and promising combinations of drugs targeting apoptosis * Targeting the PI3K pathway: understanding the intricacies of this complex biology and precisely how targeted drugs can be leveraged therapeutically * Targeting the cancer epigenome: pharmacologic features of drugs targeting the epigenome and future prospects for targeting various aspects of epigenetic control * Targeting the tumour proteome: understanding the mechanisms of protein degradation in cancer including both older drugs like proteasome inhibitors, and newer PROTAC based approaches Written primarily for scientists and physicians in both the public and private sectors, Targeting Oncogenic Drivers and Signaling Pathways in Lymphoid Malignancies: From Concept to Practice is a comprehensive reference work for those interested in the growing area of Precision Cancer Therapies. Seamlessly integrating the basic and applied science, this volume will be an indispensable reference for those interested in translating the most important advances in science to innovative novel treatments for patients.
Dieser Download kann aus rechtlichen Gründen nur mit Rechnungsadresse in A, B, BG, CY, CZ, D, DK, EW, E, FIN, F, GR, HR, H, IRL, I, LT, L, LR, M, NL, PL, P, R, S, SLO, SK ausgeliefert werden.
Die Herstellerinformationen sind derzeit nicht verfügbar.
Autorenporträt
Owen A. O'Connor, M.D., Ph.D. is an American Cancer Society Research Professor at the University of Virginia Comprehensive Cancer Center. He completed his training in Internal Medicine at the New York Presbyterian Hospital at Weill Cornell University Medical School, a Fellowship in Hematology and Oncology at Memorial Sloan Kettering Cancer Center and a Fellowship in Clinical Pharmacology at Weill Cornell. He has been recognized as one of the Top Physicians in Cancer in the U.S. and is recognized by the Irish Government as one of the top 50 Irish Americans in Science and Medicine. Stephen M. Ansell, M.D., Ph.D. is the Dorotha W. and Grant L. Sundquist Professor of Hematologic Malignancies Research and the Chair of the Division of Hematology at Mayo Clinic. He received his medical degree from the University of Pretoria, South Africa and then completed a fellowship in Hematology and Medical Oncology at Mayo Clinic. His research focuses on optimizing antitumor immune function in B-cell malignancies. He received the Ernst Beutler Award from the American Society of Hematology in 2021 in recognition of his work. John F. Seymour MBBS Ph.D. heads the Department of Haematology of the Peter MacCallum Cancer Centre & the Royal Melbourne Hospital and is Professor of Medicine at the University of Melbourne. He completed a translational research fellowship at the MD Anderson Cancer Center in Houston, and has received their Distinguished Alumnus award. His work is focused on new drug development in lymphoid malignancies. He was awarded Membership of the Order of Australia, and elected to the Australian Academy of Health and Medical Sciences for his contributions to the field.
Inhaltsangabe
List of Contributors xix
Volume Foreword xxiv
Volume Preface xxvi
Series Preface xxviii
Section I Biological Basis of the Lymphoid Malignancies 1
1 Fundamental Principles of Lymphomagenesis 3 Pierre Sujobert, Philippe Gaulard, and Laurence de Leval
2 Identifying Molecular Drivers of Lymphomagenesis 12 Jennifer Shingleton and Sandeep S. Dave
3 Characterizing the Spectrum of Epigenetic Dysregulation Across Lymphoid Malignancies 25 Sean Harrop, Michael Dickinson, Ricky Johnstone, and Henry Miles Prince
4 Animal Models of Lymphoid Malignancies 40 Anjali Mishra
Section II Targeting the PI3 Kinase-AKT-mTOR Pathway 53
5 Principles of PI3K Biology and Its Role in Lymphoma 55 Ralitsa R. Madsen
6 Pharmacologic Differentiation of Drugs Targeting the PI3K-AKT-mTOR Signaling Pathway 71 Inhye E. Ahn, Jennifer R. Brown, and Matthew S. Davids
7 Clinical Experience with Phosphatidylinositol 3-Kinase Inhibitors in Hematologic Malignancies 86 Alessandro Broccoli and Pier Luigi Zinzani
9 PI3 Kinase, AKT, and mTOR Inhibitors 113 Joel McCay and John G. Gribben
Section III Targeting Programmed Cell Death 131
10 Principles for Understanding Mechanisms of Cell Death and Their Role in Cancer Biology 133 Sarah T. Diepstraten, John E. La Marca, David C.S. Huang, and Gemma L. Kelly
11 Pharmacologic Features of Drugs Targeting BCL2 Family Members 151 Jennifer K. Lue and Owen A. O'Connor
12 Clinical Experience with Pro-Apoptotic Agents 165 Thomas E. Lew and John F. Seymour
13 Promising Combinations of Drugs Targeting Apoptosis 186 William G. Wierda
Section IV Targeting the Cancer Epigenome 197
14 The Role of Epigenetic Dysregulation in Lymphoma Biology 199 Qing Deng and Michael R. Green
15 Quantitating and Characterizing the Effects of Epigenetic Targeted Drugs 209 Emily Gruber, Alexander C. Lewis, and Lev M. Kats
16 Clinical Experience with Epigenetic Drugs in Lymphoid Malignancies 225 Enrica Marchi, Ipsita Pal, and John Sanil Manavalan
17 Future Prospects for Targeting the Epigenome in Lymphomas 236 Yusuke Isshiki and Ari Melnick
Section V Targeting the B-cell Receptor (BCR) 249
18 The Pathologic Role of BCR Dysregulation in Lymphoid Malignancies 251 Jan A. Burger
19 Pharmacologic Features of Drugs Targeting Bruton's Tyrosine Kinase (BTK) 268 Joel McCay and John G. Gribben
20 Clinical Experience with Drugs Targeting Bruton's Tyrosine Kinase (BTK) 278 Julia Aronson, Anthony R. Mato, Catherine C. Coombs, Prioty Islam, Lindsey E. Roeker, and Toby Eyre
21 Promising Combinations of BTK Inhibitors with Other Targeted Agents 287 Nicholas J. Schmidt, Michael E. Williams, and Craig A. Portell
Section VI Protein Degraders and Membrane Transport Inhibitors 301
22 The Biological Basis for Targeting Protein Turnover in Malignant Cells 303 Robert Z. Orlowski
23 Preclinical Overview of Drugs Affecting Protein Turnover in Multiple Myeloma 313 Giada Bianchi, Matthew Ho, and Kenneth C. Anderson
24 Clinical Experience on Proteasome Inhibitors in Cancer 331 Noa Biran, Pooja Phull, and Andre Goy
25 Targeting Nuclear Protein Transport with XPO Inhibitors in Lymphoma 361 Farheen Manji, Kyla Trkulja, Rob C. Laister, and John Kuruvilla
26 Heterobifunctional Degraders for the Treatment of Lymphoid Malignancies 372 Ashwin Gollerkeri, Jared Gollob, and Nello Mainolfi
Section VII Novel Targets and Therapeutic Prospects in Development 381
27 Strategies for Targeting the JAK-STAT Pathway in Lymphoid Malignancies 383 David J. Feith, Johnson Ung, Omar
Section I Biological Basis of the Lymphoid Malignancies 1
1 Fundamental Principles of Lymphomagenesis 3 Pierre Sujobert, Philippe Gaulard, and Laurence de Leval
2 Identifying Molecular Drivers of Lymphomagenesis 12 Jennifer Shingleton and Sandeep S. Dave
3 Characterizing the Spectrum of Epigenetic Dysregulation Across Lymphoid Malignancies 25 Sean Harrop, Michael Dickinson, Ricky Johnstone, and Henry Miles Prince
4 Animal Models of Lymphoid Malignancies 40 Anjali Mishra
Section II Targeting the PI3 Kinase-AKT-mTOR Pathway 53
5 Principles of PI3K Biology and Its Role in Lymphoma 55 Ralitsa R. Madsen
6 Pharmacologic Differentiation of Drugs Targeting the PI3K-AKT-mTOR Signaling Pathway 71 Inhye E. Ahn, Jennifer R. Brown, and Matthew S. Davids
7 Clinical Experience with Phosphatidylinositol 3-Kinase Inhibitors in Hematologic Malignancies 86 Alessandro Broccoli and Pier Luigi Zinzani
9 PI3 Kinase, AKT, and mTOR Inhibitors 113 Joel McCay and John G. Gribben
Section III Targeting Programmed Cell Death 131
10 Principles for Understanding Mechanisms of Cell Death and Their Role in Cancer Biology 133 Sarah T. Diepstraten, John E. La Marca, David C.S. Huang, and Gemma L. Kelly
11 Pharmacologic Features of Drugs Targeting BCL2 Family Members 151 Jennifer K. Lue and Owen A. O'Connor
12 Clinical Experience with Pro-Apoptotic Agents 165 Thomas E. Lew and John F. Seymour
13 Promising Combinations of Drugs Targeting Apoptosis 186 William G. Wierda
Section IV Targeting the Cancer Epigenome 197
14 The Role of Epigenetic Dysregulation in Lymphoma Biology 199 Qing Deng and Michael R. Green
15 Quantitating and Characterizing the Effects of Epigenetic Targeted Drugs 209 Emily Gruber, Alexander C. Lewis, and Lev M. Kats
16 Clinical Experience with Epigenetic Drugs in Lymphoid Malignancies 225 Enrica Marchi, Ipsita Pal, and John Sanil Manavalan
17 Future Prospects for Targeting the Epigenome in Lymphomas 236 Yusuke Isshiki and Ari Melnick
Section V Targeting the B-cell Receptor (BCR) 249
18 The Pathologic Role of BCR Dysregulation in Lymphoid Malignancies 251 Jan A. Burger
19 Pharmacologic Features of Drugs Targeting Bruton's Tyrosine Kinase (BTK) 268 Joel McCay and John G. Gribben
20 Clinical Experience with Drugs Targeting Bruton's Tyrosine Kinase (BTK) 278 Julia Aronson, Anthony R. Mato, Catherine C. Coombs, Prioty Islam, Lindsey E. Roeker, and Toby Eyre
21 Promising Combinations of BTK Inhibitors with Other Targeted Agents 287 Nicholas J. Schmidt, Michael E. Williams, and Craig A. Portell
Section VI Protein Degraders and Membrane Transport Inhibitors 301
22 The Biological Basis for Targeting Protein Turnover in Malignant Cells 303 Robert Z. Orlowski
23 Preclinical Overview of Drugs Affecting Protein Turnover in Multiple Myeloma 313 Giada Bianchi, Matthew Ho, and Kenneth C. Anderson
24 Clinical Experience on Proteasome Inhibitors in Cancer 331 Noa Biran, Pooja Phull, and Andre Goy
25 Targeting Nuclear Protein Transport with XPO Inhibitors in Lymphoma 361 Farheen Manji, Kyla Trkulja, Rob C. Laister, and John Kuruvilla
26 Heterobifunctional Degraders for the Treatment of Lymphoid Malignancies 372 Ashwin Gollerkeri, Jared Gollob, and Nello Mainolfi
Section VII Novel Targets and Therapeutic Prospects in Development 381
27 Strategies for Targeting the JAK-STAT Pathway in Lymphoid Malignancies 383 David J. Feith, Johnson Ung, Omar
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Internetauftritt der buecher.de internetstores GmbH
Geschäftsführung: Monica Sawhney | Roland Kölbl | Günter Hilger
Sitz der Gesellschaft: Batheyer Straße 115 - 117, 58099 Hagen
Postanschrift: Bürgermeister-Wegele-Str. 12, 86167 Augsburg
Amtsgericht Hagen HRB 13257
Steuernummer: 321/5800/1497
USt-IdNr: DE450055826
